Trials / Recruiting
RecruitingNCT06400485
AMT-676 in Patients With Advanced Solid Tumors
First-in-Human, Phase 1 Study of AMT-676 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Multitude Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human, non-randomized, open-label, multicenter Phase 1 study will evaluate the Maximum tolerated dose (MTD)/the recommended Phase 2 Dose (RP2D), safety, tolerability, anti-drug activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-676 in Patients with Advanced Solid Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMT-676 | Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT). |
Timeline
- Start date
- 2024-06-18
- Primary completion
- 2025-10-15
- Completion
- 2026-02-14
- First posted
- 2024-05-06
- Last updated
- 2025-05-02
Locations
13 sites across 3 countries: American Samoa, Australia, China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06400485. Inclusion in this directory is not an endorsement.